*** Bristol-Myers Shareholders Vote In Favor Of $74B Celgene Acquisition

*** Bristol-Celgene Combination Creates Cancer Drug Powerhouse With Nearly $38 billion in Yearly Sales

*** Bristol-Myers Approval For Celgene Follows Unsuccessful Activist Campaign to Undo Deal

(END) Dow Jones Newswires

April 12, 2019 10:49 ET (14:49 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Celgene Charts.